Arya Sciences Acquisition Corp. II (NYSE:ARYB) announced in an 8-K filing that it has secured shareholder approval for its business combination with biotech company Crevel Therapeutics in a vote held earlier today.
The parties expect to close this transaction October 27 and the shares and warrants of the combined entity are set to begin trading Wednesday, October 28 under the ticker symbols “CERE” and “CEREW,” respectively.
Shares representing 74.78% of the company’s total took part and approved all proposals by wide margins. However, about 15% of shares voted against proposals allowing the combined entity’s board to issue new preferred shares and removing the ability of shareholders to take action via written consent rather than an approved meeting. The filing did not disclose redemption figures.
Arya Sciences II announced its $847 million business combination with Cerevel on July 30. Cerevel is developing a variety of potential treatments for neurological diseases.
For a description all of the proposals voted on at the special meeting, click HERE.
AGBA (NASDAQ:AGBA) stock is up over +90% this morning following a +211% premarket spike on news it has signed a definitive agreement to combine with social streaming video platform Triller. AGBA, the company itself, was formed by the $555 million combination between a SPAC of the same name and TAG Companies, a financial services firm...
At the SPAC of Dawn Since closing its combination with DHC last month, AI customer engagement firm BEN (NASDAQ:BNAI) has rolled out new partnerships with call center and healthcare clients. And, while it faces a fair bit of competition in the chatbot realm, several high-profile institutions have demonstrated that creating one that provides useful services...
Blue Ocean (NASDAQ:BOCN) provided significantly more texture today in the presentation for its $275 million combination with Asian digital media group TNL Mediagene, which it expects to hit profitability in the second half of the year despite a slight shakeup in financing for the transaction. The first big update in the first investor deck is...
At the SPAC of Dawn A brand new market may have just opened up for space de-SPACs as NASA administrator Bill Nelson announced a shift in the agency’s $11 billion program for a mission to return samples from Mars. Rather than rely on the agency’s internal technologies that would be predicted to get a sample...
Overall deal flow between SPACs and biotech firms has slowed over the last year, but some pending FDA changes could breathe new life into particular business models within the space. In particular, the FDA has asked Congress as part of its 2025 Legislative Proposals to eliminate the interchangeability designation for biosimilar medications, claiming the existing...